Non-small Cell Lung Cancer(NSCLC)
Conditions
Keywords
Circulating tumor cells(CTCs), Traditional Chinese Medicine(TCM), Myeloid-derived suppressor cells(MDSCs)
Brief summary
Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells(CTCs) play a key role in the process of distant metastasis. The investigators' study will elaborate the clinical significance of CTCs intervented by Traditional Chinese Medicine(TCM) in lung cancer from the diagnosis and clinical staging,metastasis and recurrence, individual treatment and prognosis and so on, in order to provide a new direction for the treatment of lung cancer.
Detailed description
Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells play a key role in the process of distant metastasis.In recent years, research results have shown that CTCs may become a emerging marker and new target in the treatment of lung cancer. The investigators' study will elaborate the clinical significance of CTCs intervented by TCM in lung cancer from the diagnosis and clinical staging,metastasis and recurrence, individual treatment and prognosis and so on, in order to provide a new direction for the treatment of lung cancer.
Interventions
DRUGJinFuKang
po.tid.30ml
DRUGCisplatin
According to the individual patient's condition
DRUGPemetrexed
According to the individual patient's condition
Sponsors
Shanghai University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
1. Complete resection was accepted in IIa \ Ⅲa stage, and the pathological changes could confirmed as non small cell lung cancer patients; 2. Patients receiving chemotherapy for the first time in 6 weeks after surgery; 3. Age from 18 Years to 70 Years; 4. The liver and renal function were normal,and no other disease. 5. Patients compliance is good ang can understand the situation of this study and signed informed consent
Exclusion criteria
1. Patients without clear pathological diagnosis; 2. The expected survival period is morn than 6 months; 3. Patients with serious diseases such as heart, liver, kidney and hematopoietic system; 4. Patients with pregnancy or lactation; 5. Persons with a history of less control.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival | The progression disease is assessed based on CT or PET-CT every six months from date of randomization and the endpoints is the date of first documented progression or date of death due to lung cancer,assessed up to Two years. | It is decided by a doctor via the clinical examinations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Circulating Tumor Cell | 24months | It is decided by a doctor via the clinical examinations |
| Overall survival | Two years | It is decided by a doctor via the clinical examinations |
Outcome results
None listed